Business
Axsome Therapeutics Announces Publication of Post-hoc Analysis of Sunosi® Effect on Excessive Daytime Sleepiness in Narcolepsy or Obstructive Sleep Apnea Patients with a History of Depression in the Journal of Psychiatric Research
NEW YORK, Sept. 07, 2022 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies
About this update from Axsome Therapeutics, Inc.
[{"type":"text","content":"NEW YORK, Sept. 07, 2022 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system (CNS) disorders, today announced the publication of a post-hoc analysis comparing the effects of Sunosi® (solriamfetol) on excessive daytime sleepiness (EDS) in patients with and without a history of depression. Sunosi is the first and only dual-acting dopamine and norepinephrine reuptake inhibitor (DNRI) indicated to improve wakefulness in adult patients with excessive daytime sleepiness (EDS) due to narcolepsy or obstructive sleep apnea (OSA). This secondary analysis included data from two 12-week, randomized, double-blind, placebo-controlled trials in adult patients with EDS associated with narcolepsy or OSA. The analysis showed that treatment with Sunosi improved EDS symptoms both in patients with and without a clinical history of depression, compared to placebo. The results also confirmed earlier findings of a high prevalence (20%– 35%) of a history of depression in participants with narcolepsy or OSA, and suggest that increased awareness of this association may have clinical significance. Common treatment-emergent adverse events were also similar in those with and without a history of depression. The article, \"Solriamfetol Treatment of Excessive Daytime Sleepiness in Participants with Narcolepsy or Obstructive Sleep Apnea with a History of Depression,\" was published in The Journal of Psychiatric Research and is available in full here. About Sunosi® (solriamfetol) Sunosi is a dual-acting dopamine and norepinephrine reuptake inhibitor shown to improve wakefulness in adults living with excessive daytime sleepiness (EDS) due to narcolepsy or obstructive sleep apnea (OSA). Sunosi received U.S. Food and Drug Administration approval on March 20, 2019 to improve wakefulness in adult patients with EDS associated with narcolepsy or OSA and was designated a Schedule IV medicine by the U.S. Drug Enforcement Agency on June 17, 2019. SK Biopharmaceuticals Co., Ltd., the discoverer of the compound, maintains rights in 12 Asian markets, including Korea, China and Japan. Sunosi has orphan drug designation for narcolepsy in the United States. More information about Sunosi, including Full Prescribing Information and Medication Guide, is avai...